AstraZeneca (AZ)’s country president for Singapore, Vinod Narayanan, outlines the challenges of taking the reins at an affiliate against the backdrop of a pandemic and how the Anglo-Swedish company’s quest for a COVID-19 vaccine has opened up new partnership opportunities in the region. Narayanan also touches on Singapore’s open ecosystem for innovation, the rapid speed of approvals for innovative therapies there, and key trends across the Asian oncology landscape.
[Growing] awareness and recognition of the burden of cancer is accelerating the push for innovative medicines and diagnostics. With the availability of newer diagnostic platforms, there is a trend towards targeted cancer medicines that offer better outcomes for patients
